Search
Now showing items 1-10 of 446
Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood
(2014)
Background Wilms tumor is the most common pediatric renal malignancy and there is a clinical need for a molecular biomarker to assess treatment response and predict relapse. The known mutated genes in this tumor type show ...
Novel regional age-associated DNA methylation changes within human common disease-associated loci
(2016)
Background: Advancing age progressively impacts on risk and severity of chronic disease. It also modifies the epigenome, with changes in DNA methylation, due to both random drift and variation within specific functional ...
miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms' Tumor Blastema
(2013)
The current SIOP treatment protocol for Wilms' tumor involves pre-operative chemotherapy followed by nephrectomy. Not all patients benefit equally from such chemotherapy. The aim of this study was to generate a miRNA profile ...
Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells
(ELSEVIER IRELAND LTD, 2010-11)
The extracellular signal-regulated kinase (ERK) has been shown to mediate cisplatin (CP)-induced toxicity to renal proximal tubule cells. Here, we demonstrate that ERK serves as the kinase that phosphorylates the pro-apoptotic ...
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
(2010)
Roche Holding AG, and its subsidiaries Genentech Inc and Chugai Pharmaceutical Co Ltd, are developing trastuzumab emtansine (trastuzumab-DM1) for the treatment of HER2+ metastatic breast cancer. Trastuzumab emtansine is a ...
p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury
(AMER PHYSIOLOGICAL SOC, 2010-05)
Arany I, Faisal A, Clark JS, Vera T, Baliga R, Nagamine Y. p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury. Am J Physiol Renal Physiol 298: F1214-F1221, 2010. First published ...
Multiple mechanisms of MYCN dysregulation in Wilms tumour
(2015-03)
Genomic gain of the proto-oncogene transcription factor gene MYCN is associated with poor prognosis in several childhood cancers. Here we present a comprehensive copy number analysis of MYCN in Wilms tumour (WT), demonstrating ...
Obligatory and facilitative allelic variation in the DNA methylome within common disease-associated loci
(2018)
Integrating epigenetic data with genome-wide association study (GWAS) results can reveal disease mechanisms. The genome sequence itself also shapes the epigenome, with CpG density and transcription factor binding sites ...
Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour
(2015-02)
Background: Wilms tumours (WTs) are characterised by several hallmarks that suggest epimutations such as aberrant DNA methylation are involved in tumour progression: loss of imprinting at 11p15, lack of recurrent mutations ...
TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
(2014-10)
Purpose: The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome. As patients receive intensified treatment, we sought to identify whether TP53 mutational status confers ...